Plasma exchanges for the treatment of severe systemic necrotizing vasculitides in clinical daily practice: Data from the French Vasculitis Study Group

Affiliation auteurs!!!! Error affiliation !!!!
TitrePlasma exchanges for the treatment of severe systemic necrotizing vasculitides in clinical daily practice: Data from the French Vasculitis Study Group
Type de publicationJournal Article
Year of Publication2015
AuteursDe Luna G, Chauveau D, Aniort J, Carron P-L, Gobert P, Karras A, Marchand-Adam S, Maurier F, Hatron P-Y, Mania A, Le Guenno G, Bally S, Bienvenu B, Cardineau E, Goulenok T, Jourde-Chiche N, Samson M, Huart A, Pourrat J, Tiple A, Aumaitre O, Puechal X, Heshmati F, Le Jeunne C, Mouthon L, Guillevin L, Terrier B, FVSG
JournalJOURNAL OF AUTOIMMUNITY
Volume65
Pagination49-55
Date PublishedDEC
Type of ArticleArticle
ISSN0896-8411
Mots-clésANCA-Associated vasculitides, Eosinophilic granulomatosis with polyangiitis, Granulomatosis with polyangiitis, Microscopic polyangiitis, Plasma exchanges, Polyarteritis nodosa
Résumé

The use of plasma exchanges (PLEX) in systemic necrotizing vasculitides (SNV) still need to be codified. To describe indications, efficacy and safety of PLEX for the treatment of SNV, we conducted a multicenter retrospective study on patients with ANCA-associated vasculitis (AAV) or non-viral polyarteritis nodosa (PAN) treated with PLEX. One hundred and fifty-two patients were included: GPA (n = 87), MPA (n = 56), EGPA (n = 4) and PAN (n = 5). PLEX were used for rapidly progressive glomerulonephritis (RPGN) in 126 cases (86%), alveolar hemorrhage in 64 cases (42%), and severe mononeuritis multiplex in 23 cases (15%). In patients with RPGN, there was a significant improvement in renal function compared to baseline value (P < 0.0001), the plateau being reached at month 3 after PLEX initiation, and estimated glomerular filtration rate improved especially as the number of PLEX increased. In patients with alveolar hemorrhage, mechanical ventilation was discontinued in all patients after a median time of 15 days. Patients treated for mononeuritis multiplex showed improvement of severe motor weakness. After a median follow of 22 months, 18 deaths (12%) were recorded, mainly in patients with RPGN and within the first 6 months. Incidence of end-stage renal disease and/or death was similar between groups of different baseline renal function, but was increased in MPO-ANCA compared to PR3-ANCA. Adverse events attributable to FLEX were recorded in 63%. No death occurred during PLEX. This large series describes indications, efficacy and safety of FLEX in daily practice. Randomized controlled studies are ongoing to define optimal indications, FLEX regimen and concomitant medications. (C) 2015 Elsevier Ltd. All rights reserved.

DOI10.1016/j.jaut.2015.08.003